Abstract LBA44
Background
Combining immunotherapy and anti-angiogenic agents may enhance immune response by reversing the immunosuppressive microenvironment. We conducted a randomized, open-label, phase 2 trial to assess camrelizumab (CAM, an anti-PD-1 antibody) plus famitinib (FAM, a multi-targeted TKI against VEGFR2/3) versus CAM alone and investigator’s choice of chemotherapy (chemo) for recurrent or metastatic cervical cancer (R/M CC).
Methods
Patients (pts) with R/M CC who failed prior platinum-based chemo were enrolled. Prior anti-PD-1/PD-L1/CTLA-4 treatment was not allowed. Pts were randomized to receive CAM 200 mg IV Q3W with (cohort A) or without (cohort B) FAM 20 mg PO QD, or investigator’s choice of chemo (cohort C) every 3-week cycle. The primary endpoint was ORR per RECIST v1.1 assessed by blinded independent central review (BICR).
Results
At data cutoff on April 21, 2023, 194 pts were randomized (cohort A n=105, cohort B n=54, cohort C n=35), and 46 pts (23.7%) remained on treatment. 77.8% of pts had squamous CC, 63.9% were PD-L1 positive, 31.4% received prior targeted therapy. The median follow-up duration was 9.9 months (IQR 7.3-15.1). Antitumor activities are shown in the table. Treatment-related adverse events (TRAEs) occurred in 100%, 94.3%, and 100% of pts, respectively. Grade ≥3 TRAEs were reported in 84.8%, 15.1%, and 60.0% of pts, respectively, with the most common ones being decreased neutrophil count (23.8%, 1.9%, 30.0%), hypertension (22.9%, 0, 0), decreased white blood cell count (20.0%, 0, 33.3%), and anemia (20.0%, 1.9%, 13.3%). Dose discontinuation due to AEs occurred in 19.0%, 5.7%, and 0 pts, respectively. Treatment-related death was reported in two pts (1.9%) in cohort A (acute coronary syndrome, infection and sepsis). Table: LBA44
Summary of efficacy
Cohort A (n=105) | Cohort B (n=54) | Cohort C (n=35) | |
BICR-assessed | |||
CR | 9 (8.6) | 3 (5.6) | — |
PR | 34 (32.4) | 10 (18.5) | — |
ORR | 41.0 (31.5-51.0) | 24.1 (13.5-37.6) | — |
DCR | 75.2 (65.9-83.1) | 55.6 (41.4-69.1) | — |
PFS (mo) | 7.2 (6.1-12.4) | 4.0 (2.1-6.1) | — |
Investigator-assessed | |||
CR | 4 (3.8) | 2 (3.7) | 1 (2.9) |
PR | 41 (39.0) | 10 (18.5) | 4 (11.4) |
ORR | 42.9 (33.2-52.9) | 22.2 (12.0-35.6) | 14.3 (4.8-30.3) |
DCR | 74.3 (64.8-82.3) | 53.7 (39.6-67.4) | 42.9 (26.3-60.7) |
PFS (mo) | 8.1 (6.2-12.4) | 4.1 (2.1-5.1) | 2.9 (2.0-6.2) |
12-months OS rate | 80.3 (70.7-87.0) | 71.9 (55.8-83.0) | 59.7 (40.9-74.3) |
Conclusions
CAM plus FAM showed improved antitumor activity than CAM alone or investigator’s choice of chemo in pts with R/M CC, with a tolerable safety profile.
Clinical trial identification
NCT04680988 (registered on December 23, 2020).
Editorial acknowledgement
We would like to thank Yanwen Wang (Jiangsu Hengrui Pharmaceuticals) for editorial assistance in the writing of this abstract.
Legal entity responsible for the study
Jiangsu Hengrui Pharmaceuticals.
Funding
Jiangsu Hengrui Pharmaceuticals.
Disclosure
X. Zhou: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals. Y. Wang: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals. Q. Wang: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
Invited Discussant LBA45 and 746MO
Presenter: Kosei Hasegawa
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
745MO - Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study
Presenter: Kathleen Moore
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
747MO - First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
Presenter: Isabelle Ray-Coquard
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 745MO and 747MO
Presenter: Mansoor Raza Mirza
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast